Exabis Library
Welcome to the e-CCO Library!
OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP026: The TOPPIC Trial: a randomised, double-blind parallel-group trial of mercaptopurine versus placebo to prevent recurrence of Crohn’s disease following surgical resection in 240 patients
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP027: Anti-tumour necrosis factor therapy is associated with increased risk of postoperative morbidity after surgery for ileocolonic Crohn’s disease: outcome analysis in a prospective nationwide cohort of 592 patients conducted by the GETAID chirurgie group
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in colitis-associated colorectal cancer
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP027: SUCNR1 receptor mediates intestinal fibrosis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP028: Gut specific regulatory T cells – a new frontier for Crohn's disease therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP028: Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn’s disease: results from the UNITI-1 and UNITI-2 studies
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP028: Single cell RNA sequencing of t-cells in Crohn’s disease identifies tissue specific drug targets
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP029: Characterisation of Paneth cell dysfunction in XIAP-deficient mice
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP029: Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohn’s disease: a prospective, randomised, multicentre trial (Tailorix)
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP029: Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP02: Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn's disease patients stopping infliximab
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP02: The breastmilk proteomics of women with Inflammatory Bowel Disease (IBD) and its impact on fecal calprotectin and microbiota composition in their babies
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP02: The role of PTPN2 SNP in the pathogenesis of fibrosis in Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP02: Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP03 Reduced need for surgery and medical therapy after early ileocaecal resection for Crohn’s disease: Long-term follow-up of the LIR!C trial
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP030: Factors associated with the first trough level of infliximab at week 2 that predicts short- and long-term outcomes in ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP030: Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantation
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP030: Loss of PTPN2 in dendritic cells promotes T-cell activation and expression of co-stimulatory molecules
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM